PE-22-28

PE-22-28 was developed from spadin, an endogenous 17-residue peptide (a sortilin propeptide fragment) identified as a TREK-1 blocker. Spadin undergoes rapid in-vivo clearance, motivating researchers to screen shorter analogs with improved stability. Djillani et al. (2017) synthesized a library of truncated spadin fragments and identified a 7-amino-acid peptide corresponding to residues 22–28 of spadin's sequence as a lead candidate. This fragment—Gly-Val-Ser-Trp-Gly-Leu-Arg—retained selective TREK-1 inhibitory activity and demonstrated greater stability compared to the parent peptide in the experimental systems examined. The design strategy was guided by spadin degradation products; subsequent analogs incorporating N-terminal glycine-to-alanine substitutions were also characterized for TREK-1 activity. This work illustrates iterative truncation-based optimization around an endogenous peptide scaffold.

Biophysical characterization of PE-22-28 was conducted using whole-cell patch-clamp recordings in HEK293 cells transfected with human TREK-1 (Djillani et al., 2017). In these assays, PE-22-28 rapidly inhibited TREK-1 currents; parallel assay of the parent spadin peptide under the same conditions indicated lower inhibitory activity, motivating the truncation approach. The selectivity panel examined the closely related K2P channels TREK-2 and TRAAK; PE-22-28 did not produce significant current inhibition at either. No published crystal or cryo-EM structure of the PE-22-28–TREK-1 complex has been reported; by analogy with other characterized K2P blockers, the compact 7-residue sequence is proposed to access the extracellular pore region of the channel.

Cellular endpoints relevant to neuroplasticity have been examined using PE-22-28 in mouse systems. In cultured mouse cortical neurons, PE-22-28 and related analogs were assessed for PSD-95 expression, a postsynaptic density scaffolding protein used as a marker in synaptogenesis assays (Djillani et al., 2017). In live mice receiving short-term PE-22-28 administration, hippocampal neurogenesis markers—including BrdU-positive progenitor cells and doublecortin (DCX)-labeled neurons in the dentate gyrus—were quantified by immunohistochemistry. These assays were designed to probe whether TREK-1 inhibition engages downstream neuroplasticity signaling cascades; the specific molecular pathways linking channel block to these cellular endpoints remain under investigation.

PE-22-28 has been applied in established mouse behavioral paradigms used in CNS neuropharmacology research. Forced swim and novelty-suppressed feeding tests—standard rodent assays for characterizing neurochemical states—were used to measure behavioral endpoints in treated versus control animals (Djillani et al., 2017). In a separate experimental context, sortilin-derived peptides including PE-22-28 were evaluated in a mouse middle cerebral artery occlusion (MCAO) model, a laboratory ischemia system used to study experimental stroke. Motor and cognitive functional assessments were among the endpoints examined after experimental occlusion in this rodent model (Pietri et al., 2019). These studies employ standard neurological assessment batteries alongside cellular and histological markers, exclusively within an animal-model framework.

Beyond CNS research contexts, PE-22-28 has been examined in endocrine cell assays. Daziano et al. (2021) studied spadin and PE-22-28 in rat insulinoma (INS-1E) cells subjected to cytokine stress (IL-1β challenge). TREK-1 expression was confirmed in this cell line. Assay endpoints included membrane potential measurements, intracellular Ca²⁺ influx, CaM-kinase and CREB phosphorylation as downstream signaling readouts, caspase activity as an apoptotic marker, and β-cell proliferation markers. The experimental framework was framed around the hypothesis that K⁺ channel blockade engages Ca²⁺-dependent intracellular signaling cascades in β-cells. These findings are interpreted at the cellular signaling level; the study uses PE-22-28 as a molecular tool for dissecting TREK-1's role in β-cell biology.